Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

Topline data for registrational Phase 2 trial of KYV-101 in stiff person syndrome (SPS) and
BLA submission anticipated in 1H 2026

Registrational Phase 3 KYV-101 trial in myasthenia gravis (MG) to include ~60 patients with enrollment to initiate by
year-end 2025; interim Phase 2 data expected in Q4 2025

Read more at globenewswire.com